title: Multidisciplinary management of hepatocellular carcinoma.
abstract: Hepatocellular carcinoma is a leading cause of death in patients with cirrhosis. Management algorithms continually are increasing in sophistication and involve application of single and multimodality treatments, including liver transplantation, hepatic resection, ablation, transarterial chemoembolization, radioembolization, and systemic chemotherapy. These treatments have been shown to increase survival times. As many as 75% of patients with limited-stage disease who are given curative therapies survive 5 years, whereas less than 20% of untreated patients survive 1 year. Treatment can be optimized based on the patient's tumor stage, hepatic reserve, and functional status. However, because of the heterogeneity in presentation among patients, a multidisciplinary approach is required to treat hepatocellular carcinoma, involving hepatologists, surgeons, interventional radiologists, and oncologists. We present each specialist's viewpoint on controversies and advances in the management of hepatocellular carcinoma.
authors.affiliation: Department of Medicine, University of California San Francisco, San Francisco, California, USA. guyj@sutterhealth.org
authors.forename: Jennifer
authors.initials: J
authors.lastname: Guy
authors.forename: Robin K
authors.initials: RK
authors.lastname: Kelley
authors.forename: John
authors.initials: J
authors.lastname: Roberts
authors.forename: Robert
authors.initials: R
authors.lastname: Kerlan
authors.forename: Francis
authors.initials: F
authors.lastname: Yao
authors.forename: Norah
authors.initials: N
authors.lastname: Terrault
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome